Form 8-K · Current report
Baxter International 8-K, filed Jul 30, 2026
- Filed
- CIK
- 0000010456
- Accession no.
- 0001628280-26-050795
Summary
Baxter International reported second-quarter 2026 sales of $2.96 billion, up 5% on reported and organic bases, with GAAP diluted EPS of $0.26 and adjusted diluted EPS of $0.56, and raised its full-year 2026 outlook. CEO Andrew Hider said the results exceeded expectations on the top and bottom lines, driven by operating performance and an additional tariff refund benefit, while the board declared a quarterly cash dividend of $0.01 per share.
Key points
- Baxter raised full-year 2026 reported sales growth guidance to 3%-4% from flat to 1%, organic sales growth to 2%-3%, and adjusted diluted EPS from continuing operations to $1.95-$2.15 from $1.85-$2.05.
- Second-quarter sales grew in all segments and divisions; Medical Products & Therapies sales were about $2.1 billion, up 7% reported and 5% organic, while Healthcare Systems & Technologies sales were about $801 million, up 4% on both bases.
- Adjusted diluted EPS fell 5% year over year, partly offset by a $0.11 per diluted share benefit from an IEEPA tariff refund.
- The board declared a quarterly cash dividend of $0.01 per share, payable Oct. 1, 2026, to stockholders of record Aug. 28, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On July 30, 2026, Baxter International Inc. (the Company) issued an earnings press release for the period ended June 30, 2026. The press release, including attachments, is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.